Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, Mantle-Cell 2Lymphoma 2Leukemia 2Recurrence 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, B-Cell 1

Interventions

Cyclophosphamide 9ofatumumab 8fludarabine 5Rituximab 5fludarabine phosphate 4Bendamustine Hydrochloride 4venetoclax 3ibrutinib 3acalabrutinib 3Melphalan 3obinutuzumab 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Lenalidomide 2Immunotherapy, Adoptive 2Busulfan 2Bortezomib 2Alemtuzumab 2zanubrutinib 1thymoglobulin 1tenofovir alafenamide 1pomalidomide 1pivalyloxymethyl butyrate 1pirtobrutinib 1pegaspargase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, B-Cell × Chlorambucil × Clear all
NCT01563055 2015-08-10

A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia

GlaxoSmithKline

Phase 2 Completed
10 enrolled 52 charts
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡